For future public health emergencies, the Centers for Medicare & Medicaid Services should improve how it sets Medicare rates for clinical diagnostic laboratory tests under the Clinical Laboratory Fee Schedule and communicates with stakeholders involved in setting the rates, the Department of Health and Human Services’ Office of Inspector General advised last week. When CMS was working to increase testing capacity during the COVID-19 PHE, CMS’s standard rate setting procedures did not allow Medicare Administrative Contractors to set rates that were adequate to cover the cost of conducting COVID-19 viral tests for all laboratories, OIG said. In addition, OIG said CMS may have missed opportunities to obtain important information from laboratory associations and MAC pricing coordinators when it made decisions about the new CDLT rates.

Related News Articles

Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
The AHA Sept. 3 released a study conducted by KNG Health Consulting that found Medicare patients who receive care in a hospital outpatient department are more…
Blog
In this insightful conversation hosted by Nancy Myers of the American Hospital Association, we explore how Owensboro Health (Ky.) and CredibleMind are…
Headline
The AHA Aug. 28 expressed support for the Preserving Patient Access to Accountable Care Act in comments to House and Senate sponsors of the bill. The…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…